StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.81+0.00 (0.00%)

Close on Nov 17, 2026Market cap $230.39MP/E –Yield –

Vanda Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Vanda Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -119.9%. For fiscal 2025 it was -102.0%, against -9.5% the year before. The highest annual figure on record is 50.9% in fiscal 2019.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-102.0%−92.5
FY2024Dec 31, 2024-9.5%−10.8
FY2023Dec 31, 20231.3%−1.2
FY2022Dec 31, 20222.5%−9.9
FY2021Dec 31, 202112.3%+2.9
FY2020Dec 31, 20209.4%−41.5
FY2019Dec 31, 201950.9%+37.8
FY2018Dec 31, 201813.1%+22.5
FY2017Dec 31, 2017-9.4%+2.9
FY2016Dec 31, 2016-12.3%+23.9
FY2015Dec 31, 2015-36.3%−76.5
FY2014Dec 31, 201440.2%+102.4
FY2013Dec 31, 2013-62.1%+25.3
FY2012Dec 31, 2012-87.4%−56.1
FY2011Dec 31, 2011-31.3%−51.5
FY2010Dec 31, 201020.1%+808.6
FY2009Dec 31, 2009-788.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-32.3%+7.8
Q2 FY2026Jun 30, 2026-123.7%−72.0
Q1 FY2026Mar 31, 2026-93.9%−35.0
Q4 FY2025Dec 31, 2025-246.8%−237.5
Q3 FY2025Sep 30, 2025-40.1%−29.0
Q2 FY2025Jun 30, 2025-51.7%−42.8
Q1 FY2025Mar 31, 2025-58.9%−50.2
Q4 FY2024Dec 31, 2024-9.2%−3.9
Q3 FY2024Sep 30, 2024-11.2%−11.5
Q2 FY2024Jun 30, 2024-9.0%−12.3
Q1 FY2024Mar 31, 2024-8.7%−13.9
Q4 FY2023Dec 31, 2023-5.3%−15.9
Q3 FY2023Sep 30, 20230.4%−4.7
Q2 FY2023Jun 30, 20233.3%−0.7
Q1 FY2023Mar 31, 20235.2%+15.9
Q4 FY2022Dec 31, 202210.6%+0.2
Q3 FY2022Sep 30, 20225.0%−6.1
Q2 FY2022Jun 30, 20224.0%−10.2
Q1 FY2022Mar 31, 2022-10.7%−24.5
Q4 FY2021Dec 31, 202110.4%−1.7
Q3 FY2021Sep 30, 202111.1%+1.2
Q2 FY2021Jun 30, 202114.2%+0.2
Q1 FY2021Mar 31, 202113.8%+13.0
Q4 FY2020Dec 31, 202012.1%+5.2
Q3 FY2020Sep 30, 20209.9%−159.0
Q2 FY2020Jun 30, 202014.0%−5.5
Q1 FY2020Mar 31, 20200.8%+2.1
Q4 FY2019Dec 31, 20196.9%−12.6
Q3 FY2019Sep 30, 2019168.8%+154.2
Q2 FY2019Jun 30, 201919.5%+9.8
Q1 FY2019Mar 31, 2019-1.3%−8.3
Q4 FY2018Dec 31, 201819.5%+23.7
Q3 FY2018Sep 30, 201814.6%+25.6
Q2 FY2018Jun 30, 20189.7%+13.4
Q1 FY2018Mar 31, 20187.0%+27.5
Q4 FY2017Dec 31, 2017-4.2%−2.6
Q3 FY2017Sep 30, 2017-11.0%–
Q2 FY2017Jun 30, 2017-3.6%–
Q1 FY2017Mar 31, 2017-20.4%–
Q4 FY2016Dec 31, 2016-1.6%–

More Vanda Pharmaceuticals figures

See a number that looks wrong?